Business Context and Reporting Period
This Form 8-K is a current report filed by Bicycle Therapeutics plc on August 18, 2026. The registrant is incorporated in England and Wales and trades on The Nasdaq Stock Market LLC under the symbol BCYC. The report addresses a specific corporate governance event occurring on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a personnel change and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a director:
- Resignation: Charles Swanton resigned as a Class II director of the Board of Directors, as a member of the Board's committees, and as a member of the Clinical Advisory Board.
- Effective Date: The resignation was effective immediately on August 18, 2026.
- Reason: Dr. Swanton's resignation was for personal reasons.
- Disagreement Status: The filing explicitly states the resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure. No unusual items were reported.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors and Clinical Advisory Board following Dr. Swanton's departure.
- Confirm whether the resignation triggers any changes to committee memberships or quorum requirements.
- Review subsequent filings to determine if a replacement director has been nominated or elected.